Velicept Therapeutics

101 Lindenwood Drive
Suite 400
Malvern
Pennsylvania
19355
United States

Tel: 484-318-2988
Fax: 484-324-7949

Show jobs for this employer

About Velicept Therapeutics

Velicept Therapeutics is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Dr. James C. Walker
CFO: Doug Gessl
CSO: Dr. Eliot Ohlstein
Head of Project Management: Dr. Jeffrey S. Shaver
Head of Operations: Ray Stevens
Head of Commercial Strategy: Kelly A. Copeland
Head of CMC and QA: Dale Bennyhoff
CLINICAL:
Please click here for Velicept's pipeline.

5 articles with Velicept Therapeutics